title: Design and synthesis of tetrahydrophthalimide derivatives as inhibitors of HIV-1 reverse transcriptase.
abstract: Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are one of the key components in highly active anti-retroviral therapy because of their high specificity and less toxicity. NNRTIs inhibit reverse transcriptase enzyme by binding to the allosteric site, which is 10Å away from the active site. Rapid emergence of resistance is the major problem with all anti-HIV agents. Hence, there is continuous need to develop novel anti-HIV agents active against both drug sensitive and resistance strains.
  
  
  
  All the 16 synthesized 2-(1,3-dioxo-3a,4-dihydro-1H-isoindol-2(3H,7H,7aH)-yl)-N-(substitutedphenyl) acetamide 4(a-p) analogs were characterized by Fourier transform infrared spectroscopy, proton nuclear magnetic resonance spectroscopy, mass spectroscopy, and elemental analysis. Lipinski rule of five parameters and molecular parameters like solubility, drug likeness, and drug score were derived for designed analogs using online servers like Molinspiration and Osiris property explorer. Synthesized compounds were evaluated for their HIV-1 reverse transcriptase inhibitor activity by HIV-1 RNA-dependent DNA polymerase activity assay at 2 and 20 μM concentrations.
  
  
  
  Among the 16 synthesized compounds, 4a, 4b, 4f, 4g, 4k, and 4l showed weak reverse transcriptase inhibitor activity at 20 μM concentration. For the designed compounds, there was no correlation observed between molecular modeling and in vitro studies.
authors: Department of Pharmacy, Birla Institute of Technology & Science, Pilani Rajasthan 333031, India. murugesaa789@gmail.com.
authors: Ashok
authors: A
authors: Penta
authors: Swastika
authors: S
authors: Ganguly
authors: Sankaran
authors: S
authors: Murugesan
references: J Med Chem. 2005 Jun 2;48(11):3858-73
references: 15916438
references: Antiviral Res. 2010 Jan;85(1):75-90
references: 19781578
references: J Med Chem. 2012 Aug 23;55(16):7219-29
references: 22856541
references: J Med Chem. 1996 Apr 12;39(8):1589-600
references: 8648598
references: J Med Chem. 2006 Aug 10;49(16):4834-41
references: 16884295
references: J Med Chem. 2005 Mar 24;48(6):1930-40
references: 15771437
references: J Med Chem. 2003 Feb 27;46(5):768-81
references: 12593657
references: J Med Chem. 2012 Dec 13;55(23):10601-9
references: 23137340
references: J Med Chem. 2012 Apr 26;55(8):3595-613
references: 22268494
references: Acta Crystallogr D Biol Crystallogr. 2004 Aug;60(Pt 8):1355-63
references: 15272157
references: J Med Chem. 2005 Mar 24;48(6):1901-9
references: 15771434
references: J Med Chem. 2012 Sep 13;55(17):7583-92
references: 22889416
references: Bioorg Med Chem. 2002 Sep;10(9):3067-73
references: 12110331